Biomerica Reports First Quarter Fiscal 2027 Financial ResultsGlobeNewsWire · Oct 16, 2026
Head-To-Head Survey: Biomerica (NASDAQ:BMRA) versus Cytosorbents (NASDAQ:CTSO)Defense World · Sep 10, 2026
Biomerica Reports Fiscal 2026 Year-End Financial ResultsGlobeNewsWire · Sep 1, 2026
Biomerica Announces $2.23 Million FinancingGlobeNewsWire · Aug 27, 2026Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste.
| Date | Est. | Actual | |
|---|---|---|---|
| Oct 15, 2026 | -$1.20 | -$0.37 | Beat |
| Aug 31, 2026 | -$1.20 | -$0.38 | Beat |
| Apr 13, 2026 | -$1.20 | -$0.44 | Beat |
| Jan 14, 2026 | $0.32 | -$0.45 | Miss |
| Oct 14, 2025 | $0.32 | $0.00 | Miss |
| Aug 29, 2025 | $0.16 | -$0.16 | Miss |